

Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





BCR-ABL1 Non-Standard p230

Alternative Name

BCR-ABL1 p230 Translocation, BCR/ABL1 Non-Standard

Methodology

Molecular

Test Description

Real-time RT-PCR for detection of t(9;22) BCR-ABL1 fusion transcripts that result in p230 (e19a2) fusion proteins. Analytical sensitivity is 0.1%. Results are reported as Detected or Not Detected. Test can be ordered as a reflex when can be ordered as a reflex when BCR-ABL1 Standard p210, p190 is negative.

Clinical Significance

Subsets of patients with Ph1+ chronic myeloid leukemia (CML) have a unique breakpoint within the BCR gene on chromosome 22. This breakpoint is 3' to the more common breakpoints found in patients with CML and ALL and can lead to e19a2 fusion transcript. Thus, p230 BCR-ABL1 contains additional BCR coding sequences that are not found in the p190 or p210 variants. The incidence of this translocation is very rare, but may lead to falsely negative molecular testing when the molecular testing is designed to detect breakpoints in E1, E13 or E14. Although some studies suggested that the course of CML in patients with p230 is milder than that in average CML, response to therapy is similar. However, very little literature is available due to the rarity of this abnormality.

Specimen Requirements

- Bone Marrow: 2 mL EDTA tube. Sodium heparin acceptable.
- Peripheral Blood: 5 mL EDTA tube. Sodium heparin acceptable.

Note: Test is RNA-based, NOT suitable for Freeze & Hold option.

Storage & Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible; specimens <7 days old preferred.

CPT Code(s)*

81208

New York Approved

No

Level of Service

Global

Turnaround Time



Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way Fort Myers, FL 33912

Phone: 239.768.0600/ Fax: 239.690.4237

neogenomics.com

© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved. All other trademarks are the property of their respective owners

Rev. 052024